SAS Output

10-APR-2021 6:10

GU ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 1273 344 163 98 54 21 4 09/24/2018 286 132
            344 163 98 54 21 4      
 
    2 Y 1 Standard Systemic Therapy Only 1273 113 55 26 17 8 1 09/24/2018    
        2 SST + Surgery/RT   114 56 26 14 8 1      
            227 111 52 31 16 2      
 
  S1806-Blad, MIBC, ChemoRT +/- Atezolizumab 1 Y 0 Initial Registration 475 153 95 49 28 12 3 06/03/2019 283 130
            153 95 49 28 12 3      
 
    2 Y 1 Chemo + RT 475 72 44 25 13 5 1 06/03/2019    
        2 Chemo + RT + Atezolizumab   68 43 22 12 5 2      
            140 87 47 25 10 3      
 
  S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only 1 Y 0 Pre-Rand. SST 332 1 1 1 1 0 0 03/08/2021 59 34
            1 1 1 1 0 0      
 
    2 Y 2 Nephrectomy + Systemic Immuno. 332 1 1 1 1 0 0 03/08/2021    
            1 1 1 1 0 0      
 
Yes A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 1 E Total Registrations   8 2 1 1 1 0 11/23/2016 62 46
            8 2 1 1 1 0      
 
  A031702-GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) 1 E Total Registrations   16 6 1 0 0 0 08/09/2019 205 96
            16 6 1 0 0 0      
 
  A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo 1 E Total Registrations   59 44 27 13 1 0 10/02/2019 229 116
            59 44 27 13 1 0      
 
    2 E Total Registrations   28 23 15 7 3 0 10/02/2019    
            28 23 15 7 3 0      
 
  EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) 0 E Total Registrations   147 45 19 0 0 0 09/29/2017 290 164
            147 45 19 0 0 0      
 
    1 E Total Registrations   153 61 36 19 7 3 09/29/2017    
            153 61 36 19 7 3      
 
  EA8171-PROS, newly diagnosed, mpMRI for pre-op stagi 1 E Total Registrations   41 18 13 1 0 0 02/11/2019 93 43
            41 18 13 1 0 0      
 
  NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel 1 E Total Registrations   4 1 0 0 0 0 08/24/2017 185 96
            4 1 0 0 0 0      
 
    2 E Total Registrations   4 1 0 0 0 0 08/24/2017    
            4 1 0 0 0 0      
 
  NRGGU005-PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT 1 E Total Registrations   6 5 4 1 0 0 03/19/2019 278 125
            6 5 4 1 0 0      
 
  NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide 1 E Total Registrations   3 3 2 1 1 0 09/25/2020 158 70
            3 3 2 1 1 0      
 
No A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs 0 E Total Registrations   93 31 11 3 1 1 05/03/2018 274 151
            93 31 11 3 1 1      
 
    1 E Total Registrations   85 24 8 3 2 1 05/03/2018    
            85 24 8 3 2 1      
 
  A031701-Bladder, ddGC for MIBC with DDR Tumor Alt 1 E Total Registrations   7 4 0 0 0 0 12/17/2018 141 59
            7 4 0 0 0 0      
 
    2 E Total Registrations   7 6 2 2 0 0 12/17/2018    
            7 6 2 2 0 0      
 
  A031801-GU, mRCC, Cabozantinib +/- Radium-223 1 E Total Registrations   2 2 2 0 0 0 11/06/2020 8 4
            2 2 2 0 0 0      
 
  EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT 1 E Total Registrations   7 2 1 1 0 0 04/25/2019    
            7 2 1 1 0 0      
 
  EA8153-Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) 1 E Total Registrations   31 8 5 2 1 0 08/08/2018 209 94
            31 8 5 2 1 0      
 

10-APR-2021 6:10

GU Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S1937 Blad, Mets, Eribulin +/- Gem vs SOC 1 Randomization 16-Feb-21 15 13